Introduction {#Sec1}
============

Atherosclerotic renal artery stenosis (RAS) is a common condition that may lead to hypertension, progressive renal dysfunction and cardiovascular morbidity \[[@CR1]\]. It frequently, in up to 40% of patients, accompanies coronary artery and lower limb atherosclerotic disease \[[@CR2], [@CR3]\].

There is still controversy on the clinical efficacy of endovascular therapy of RAS. The randomized trials of balloon angioplasty or stenting for renal artery stenosis compared with medical therapy alone could not show apparent advantage of this type of therapy. Some of those trials were limited by enrollment of small number of patients, frequent crossover from medical to interventional therapy compromising the intention-to-treat results, or selection of patients that are not expected to show clear benefit \[[@CR4]--[@CR7]\]. The preliminary results of ASTRAL \[[@CR8]\] trial also showed ambiguous findings related to incremental value of revascularization in addition to medical therapy alone. Publication of this study and anticipated results of CORAL trial are expected to shed more light to this controversial issue.

Concerning revascularization strategy several studies demonstrated equal or better hemodynamic result for stents as compared with balloon angioplasty with higher success rate and long-term patency \[[@CR9]--[@CR13]\]. Currently the use of stents is the preferred treatment option for patients requiring revascularization of RAS, mainly for ostial lesions which tend to recoil due to their elastic nature.

The primary aim of this prospective, multicentre, ODORI registry was to assess the immediate technical success, and impact on blood pressure and renal function up to one year, in a large cohort of patients undergoing Tsunami peripheral stent placement.

Methods {#Sec2}
=======

Inclusion/Exclusion Criteria {#Sec3}
----------------------------

Patients, at least 18 years old, with atherosclerotic renal artery stenosis of more than 50%, judged by the clinicians as indicated for renal revascularization, were enrolled in the study.

Excluded were patients with fibromuscular dysplasia, total occlusion, spontaneous dissection or in-stent restenosis of renal artery, stenosis of a transplant or bypass graft anastomosis, aneurysm of abdominal aorta larger than 45 mm in diameter, current pregnancy, and contraindication to contrast media, aspirin, thienopyridines, heparin or any other therapy as required for elective intervention.

The ODORI registry was conducted in 36 institutions (listed in Appendix [1](#Sec18){ref-type="sec"}) from February 2005 to February 2007. The study was carried out according to the Declaration of Helsinki, and respecting all country-specific regulatory requirements. The protocol was reviewed and approved by the ethics committee of participating hospitals and written informed consent was obtained from the patients prior to stent implantation.

Tsunami Peripheral Stent {#Sec4}
------------------------

Tsunami peripheral stent is a stainless-steel, laser cut, open-cells stent mounted on a rapid exchange delivery balloon catheter compatible with 0.014″ and 0.018″ guidewire. The stent design comprises 12 cells with a triple link in diameters 5 and 6 mm, and 14 cells with quadruple link in 7 mm diameter, with a strut thickness of 0.0071″ (0.18 mm). All stents are compatible with 5 Fr long sheath or 6 Fr guiding catheter. Stents were available in diameters of 5, 6 and 7 mm and in lengths of 12 and 18 mm. Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Expanded Tsunami peripheral stent

Procedure {#Sec5}
---------

Stent implantation was performed in a standard fashion via retrograde femoral, brachial or radial approach. Tsunami peripheral stent was implanted at recommended pressure and correct stent size was selected based on visual assessment.

Peri-procedural and post-procedure anticoagulant and antiplatelet therapy were according to the routine hospital practice and were left to the discretion of treating physician.

In the initial protocol patient follow-up included visits at 30 days and visit or telephone follow-up at 6 months. The protocol was later amended to include 12 months follow-up by either hospital visit or telephone follow-up. At that time 12 centres enrolling total of 134 patients agreed to extend patients follow-up. At follow-up special attention was paid to adverse event surveillance along with a detailed questionnaire about concurrent antihypertensive medications and self measured blood pressure. If the patient visited hospital blood samples were drawn for routine laboratory screening, and measurement of resting systolic and diastolic blood pressure were performed. At six and 12 months duplex ultrasonography of the renal artery and stent was conducted to assess patency.

A confirmatory angiogram was recommended if duplex ultrasound suggested restenosis.

Study Definitions and Endpoints {#Sec6}
-------------------------------

The definitions in this study are based on Guidelines for the Reporting of Renal Artery Revascularization in Clinical Trials \[[@CR14]\].

Primary endpoint of the study was acute technical success defined as angiographic residual diameter stenosis lower than 30%, calculated as the ratio of the residual target lesion lumen diameter to the diameter of the reference segment of the artery using visual estimates.

Secondary endpoints included major complications within 48 h after stent implantation, improvement in blood pressure, number of medications and serum creatinine level at 6 and 12 months, restenosis defined as more than 50% diameter stenosis at 6 and 12 months (assessed by ultrasound or angiography) and clinical patency rate at 6 and 12 months defined as absence of clinical need for target lesion revascularization (TLR).

Blood pressure outcomes were defined as follows:Cure---diastolic blood pressure ≤90 mmHg and systolic blood pressure ≤140 mmHg, in patients without antihypertensive medications.Improvement---diastolic blood pressure ≤90 mmHg and/or systolic blood pressure ≤140 mmHg on the same or reduced number of medications or a reduction in diastolic blood pressure by at least 15 mmHg with the same or a reduced number of medications.Failure---no change or inability to meet these criteria for cure or improvement.Benefit---cure or improvement

Renal function outcomes were defined as follows:Improvement of renal function, defined as increase of 20% or more from baseline estimated glomerular filtration rate (e-GFR)Worsening of the renal function, defined as decrease of 20% or more from baseline e-GFRStabilization of the renal function defined as absence of deterioration.

The duplex criteria for restenosis were according to the local preferences and defined as peak systolic velocity (PSV) \>180 cm/s and \>3.5:1 renal artery to aortic peak systolic velocity ratio. Only successful duplex recordings were considered for restenosis assessment.

Major Clinical Adverse Events {#Sec7}
-----------------------------

Major clinical adverse events (MACE) are defined as an event resulting in an additional procedure, unplanned treatment, prolonged hospitalization, transfusion, or death (e.g., arterial thrombosis treated with thrombolytic therapy, renal failure, femoral pseudoaneurysm, or hematoma requiring surgical exploration or other directed therapy, retroperitoneal bleeding). Deaths occurring within 30 days of the renal stent procedure, or during the index hospitalization are considered as a procedure-related mortality.

Study Organization {#Sec8}
------------------

All data were entered electronically on predefined case report forms. Data were stored in a central database of KIKA Medical, Paris, France. Queries were continuously generated throughout the study and sent to the investigators for resolution.

All major adverse events were assessed by an independent clinical events monitor.

Statistical Design and Analysis {#Sec9}
===============================

Analytical Plan {#Sec10}
---------------

This was an observational, non-randomized study. Therefore, the statistical analysis was based on descriptive statistical techniques. Categorical variables are presented as a rate with its 95% exact confidence interval, whenever appropriate. Continuous variables are presented as means ±1 standard deviation with their 95% confidence interval, whenever appropriate. To assess the risk factors contributing to the endpoints, Student's t-test was used for continuous variables and Fisher exact test for dichotomical variables. The analyses were made on either patient (age, gender, diabetes mellitus, hypertension, renal function) or lesion related (lesion length, reference diameter) parameters and the results are presented separately for entire population and stratified per risk groups according to the baseline values. To more correctly assess changes in some of the most relevant parameters and to avoid bias in follow-up compliance, the calculations are also performed separately for matched data at baseline and follow-up using paired t-test or McNemar's test. This analysis took into consideration only baseline values of patients which were available for follow-up at corresponding time points (6 or 12 months).

All tests were considered statistically significant when *p* \< 0.05 (alpha was set at 0.05).

Results {#Sec11}
=======

The main baseline characteristics are given in Table [1](#Tab1){ref-type="table"}. Patients were on average 70 years old, 59% male, with 49% current or previous smokers, 64% treated for lipid abnormalities, 96% treated for hypertension and 33% diabetic patients. Only 25% of patients had systolic blood pressure below 150 mmHg, while 51% of patients had serum creatinine level at or above 120μmol/l. The estimated glomerular filtration rate (GFR) lower than 30 ml/min/1.73 m^2^ was detected in 23% of the patients.Table 1Baseline patient characteristicsPatient characteristicNumber of patients enrolled251Age (years)70.0 ± 10.4Sex (M)58.6%Diabetes32.9%Smoking history49.0%Hypercholesterolemia64.2%Pulmonary edema history4.8%Hypertension95.6%Systolic blood pressure (mmHg)171 ± 26Diastolic blood pressure (mmHg)89 ± 14Creatinine (μmol/l)153 ± 123Baseline estimated GFR (ml/min/1.73m^2^)\*54.3 ± 33.3e-GFR ≥6033.0%e-GFR ≥30 \<6044.8%e-GFR \<3022.2%Numbers are means ± standard deviation, or percentages\* Estimated glomerular filtration rate using Cockcroft--Gault formula \[[@CR12]\]

The main indications for the intervention (categories not mutually exclusive) were hypertension (83%), renal salvage (39%) and cardiac indications (19%). Hypertension combined with renal insufficiency was present in 25.5%, while simultaneous presence of hypertension, renal insufficiency and cardiac insufficiency was diagnosed in 8.4% of the treated patients. Most of the patients referred for hypertension were treated for refractory hypertension. Patients indicated for treatment for renal salvage (94 patients) were diagnosed as renal dysfunction not attributable to another cause (57), renal failure after ACE inhibitors (13) and sudden unexplained worsening of renal function (24).

During the procedure 28.7% of the patients received dual antiplatelet therapy (aspirin and clopidogrel), 43.4% and 9.6% respectively, aspirin and clopidogrel alone, while 18.3% of the patients were treated without antiplatelet therapy.

In total 277 Tsunami peripheral stents were used to treat 276 lesions in 221 patients with single unilateral lesions and in 28 patients with bilateral lesions. Single functioning kidney was present in 30 (12%) patients. The reason for stenting was primary stenting in 87%, recoil after angioplasty in 8.3%, and residual pressure gradient or flow limiting dissection in 2.5% of the cases. The baseline characteristics of the treated arteries are given in Table [2](#Tab2){ref-type="table"}. Renal artery stenosis was evenly distributed between right and left renal arteries, being in an ostial position in 81.2%. Mean reference diameter was 5.9 ± 0.7 mm. The mean percent diameter stenosis of the target vessel (by angiography) was 82.3 ± 9.8% before procedure and 2.5 ± 5.4% post stent implantation.Table 2Lesion and procedure characteristicsLesions characteristicNumber of arteries treated per subject 1 artery88.8% 2 arteries11.2%Side artery/ kidney treated Left52.9% Right47.1%Location artery treated Ostium81.2% Trunk18.8%Heavily calcified lesions20.0%RVD5.9 ± 0.7Diameter artery stenosis (%)82.3 ± 9.8 \>50 \<70%16 (5.8%) ≥70 \<80%63 (29%) ≥80--100%195 (71%)Procedure characteristicsNumber stents used277Mean stents per patient1.1 ± 0.3Mean Stent diameter (mm)5.9 ± 0.65Mean Stent length (mm)14.9 ± 3.75Direct stenting75.8%Direct stenting in heavily calcified lesions75.6%Mean deployment pressure (atm)10.5 ± 2.6Technical success100%Number are percentages (number of total), or means ± SD*RVD* reference vessel diameter

The primary endpoint of the study, the acute technical success (residual diameter stenosis \<30%) was obtained in 100% of the lesions. Technical features of the stent were satisfactory with good fluoroscopic visibility, allowing precise positioning particularly in ostial lesions. Direct stenting was performed in 76% of lesions. Massive calcification was present in 20% of the lesions, but 76% of those lesions were also treated by direct stenting. In two patients an additional stent placement was required in the same session, one for dissection and one due to distal migration of the first implanted stent in a very obese patient.

One peri-procedural stent thrombosis that was successfully resolved by thrombolysis was the only major clinical adverse event during index hospitalization (Table [3](#Tab3){ref-type="table"}). The patient did not receive clopidogrel during the procedure. There were 6 additional procedural complications: three minor dissections, one partial embolization and two femoral hematomas not requiring transfusion or surgery. All complications were resolved without sequelae and none required prolonged hospital stay.Table 3In-hospital and long-term major adverse eventsEventNumber%Up to 1 month follow-up Death (total)10.4Cardiovascular death10.4Stent thrombosis10.4Total major clinical events20.8From 1 month to 1 year follow-upDeath (total)114.4 Cardiovascular death41.6 Death due to renal failure31.2 Pulmonary death10.4MI10.4Target lesion revascularization20.8Total Events up to 1 yearTotal major adverse events up to 1 year follow-up166.4Total number of patients with major adverse events up to 1 year follow-up156.0Total major adverse events up to 1 year follow-up related to device or procedure62.4

One patient died in the first month after stent implantation due to pulmonary artery embolism, accounting for a 0.5% (1/251) 1-month mortality.

Six and 12-Months Follow-Up {#Sec12}
---------------------------

At six months 164 patients were available for assessment. Four patients died, two from cardiac causes, one from renal failure and one from gastrointestinal causes. One patient underwent percutaneous revascularization of the target lesion due to an in-stent restenosis of more than 70% assessed by angiography.

No other serious adverse events were reported (Table [3](#Tab3){ref-type="table"}).

At 12 months follow-up 111 out of 134 patients consented for extended follow-up were available for assessment. Seven more patients died, two each from renal failure and pneumonia and one each from pulmonary edema, cardiac failure and unknown causes. One more patient had repeat procedure for in-stent restenosis (76% stenosis by angiography).

Table [4](#Tab4){ref-type="table"} presents the impact of renal artery stenting on systolic and diastolic blood pressure. Systolic/diastolic blood pressure decreased from a mean of 171 /89 mmHg at baseline to 142/78 mmHg at 6 months (*p* \< 0.0001 vs. baseline), and 141/ 80 mmHg at 12 months (*p* \< 0.0001 vs. baseline). Pulse pressure decreased significantly (*p* \< 0.001) at both 6 and 12-months follow-up. Mean number of medications per patient at 6 months decreased from 2.63 ± 0.95 to 2.23 ± 1.15 (*p* = 0.002) and at 12 months from 2.67 ± 0.95 to 2.45 ± 1.23 (p = NS) (Fig. [2](#Fig2){ref-type="fig"}). The baseline data in this analysis were taken only for corresponding patients for whom 6 and/or 12 months follow-up were available.Table 4Changes in mean systolic and diastolic blood pressure over follow-upBlood pressureBaseline6 months*p*12 months*p*Systolic BP171 ± 26142 ± 18\<.0001141 ± 17\<.0001Diastolic BP89 ± 1478 ±  10\<.000180 ±  9\<.0001Hypertension cure (%)^a^4.9%5.7%Hypertension improvement (%)^b^77.4%70.8%Pulse pressure (mmHg)85.02 ± 22.0863.36 ± 16.15\<0.001^c^61.34 ± 14.42\<0.001^ca^Cure = diastolic blood pressure ≤90 mmHg and systolic blood pressure ≤140 mmHg, off antihypertensive medications^b^Improvement = diastolic blood pressure ≤90 mmHg and/or systolic blood pressure ≤140 mmHg on the same or reduced number of medications or a reduction in diastolic blood pressure by at least 15 mmHg with the same or a reduced number of medications^c^Paired student's *t*-testFig. 2Mean number of antihypertensive medications at 6 and 12 months for matched patients. Only patients with the data available at baseline and respective follow-up are included. \*\* *p* = 0.002, paired student's *t*-test

In the overall population, the mean serum creatinine did not change significantly (153 ± 123 μmol/l at baseline and 163 ± 127 μmol/l at 12 months) (Table [5](#Tab5){ref-type="table"}). The mean estimated glomerular filtration rate at follow-up was mainly unchanged or slightly worsened in patients with higher baseline values, while it significantly improved in patients with values below 30 ml/min/1.73 m^2^ before procedure (Table [6](#Tab6){ref-type="table"}).Table 5Estimated glomerular filtration rate at follow-up (ml/min/1.73m^2^)Estimated GFRBaseline *N* = 2516 months FUP *N* = 15412 months FUP *N* = 97Baseline GFR MILD e-GFR ≥ 60*N* = 82*N* = 45*N* = 29Mean ± SD90.32 ± 36.5985.55 ± 37.2462.03 ± 26.23Improvement8.89%3.45%Stabilization75.56%58.62%Worsening15.56%37.93%Baseline e-GFR MODERATE e-GFR ≥30 \<60*N* = 111*N* = 68*N* = 48Mean ±SD45.37 ± 8.6849.82 ± 26.8747.33 ± 15.22Improvement27.94%22.92%Stabilization54.41%62.50%Worsening17.65%14.58%Baseline GFR SEVERE e-GFR \<30*N* = 55*N* = 41*N* = 20Mean ±SD20.61 ± 7.3135.40 ± 25.46^a^36.32 ± 22.84†Improvement51.22%50.00%Stabilization39.02%50.00%Worsening9.76%0.00%Overall population*N* = 248*N* = 154*N* = 97Mean ± SD54.74 ± 34.6956.42 ± 35.6649.46 ± 22.43Improvement28.57%22.68%Stabilization56.49%58.76%Worsening14.94%18.56%Estimated glomerular filtration rate using Cockcroft-Gault formula \[[@CR14]\]^a^*p* \< 0.001 (by Mc Nemar test)Improvement = Increase of e-GFR by 20% versus baselineWorsening = Decrease of e-GFR by 20% versus baselineStabilization = No worseningTable 6Changes in mean estimated GFR values in subgroup of patients stratified according to baseline valuesBaseline value (ml/min/1.73 m^2^)Post procedure*p* Value\*30 Days*p* Value\*6 months*p* Value\*12 months*p* Value\*≥60−7.60.02−8.20.12−10.20.13−24.90.02≥30 \<60+3.40.01+14.10.01+3.90.21+1.10.54≥15 \<30+8.40.06+5.30.02+9.7\<0.001+12.90.04\<15+7.60.26+33.70.04+32. 80.18+23.90.18"+" indicates improved creatinine clearance, while "−" indicates worsening. \* PairedStudent's t-test. Only patients with the data available at baseline and respective follow-up are included

Duplex Ultrasound Results {#Sec13}
-------------------------

Successful duplex ultrasonography at six months was performed on 91 arteries and two (2.2%) arteries showed restenosis of more than 50%. One patient underwent angiography and TLR for symptomatic 76% restenosis. The other was a patient that had undergone bilateral stenting at baseline with embolic complication to the left kidney. The 6 month duplex control showed a widely patent right and totally occluded left renal artery. Because the patient was asymptomatic no additional treatment was performed.

At 12 months restenosis was detected in 3 out of 69 (4.3%) arteries assessed. Two patients were asymptomatic and no angiography was performed, while a third patient had angiographic confirmation of restenosis (76%) and underwent successful TLR by a cutting balloon.

Discussion {#Sec14}
==========

Our large, multicentre evaluation showed that the use of Tsunami peripheral stent for the treatment of renal artery stenosis is a safe and effective therapy. Significant improvement or stabilization of hypertension at 6 and 12 months after the procedure has been observed. Furthermore, 100% procedural success with no major peri-procedural complications indicates that renal artery stenting with this, newly developed, device is safe.

Catheter-based therapy for symptomatic, hemodynamically significant, atherosclerotic RAS has become the preferred method of revascularization. Balloon angioplasty has been the traditional treatment of choice, but lately, particularly for the treatment of ostial lesions, stents are more frequently used. Despite the increased use of endovascular therapy for renal artery stenosis the controversies about the net benefit of this treatment still exists \[[@CR7], [@CR8]\].

In our study stent placement significantly reduced both systolic and diastolic blood pressures at all time points as compared to baseline. Almost three out of four patients showed benefit of treatment by improvement in hypertension control, findings comparable to previously reported results \[[@CR10]--[@CR13]\]. Also the pulse pressure, frequently indicated as an important predictor of mortality, showed significant improvement at 6 and 12 months \[[@CR15]\]. However, despite the general positive effect of renal artery revascularization on blood pressure, only a small group of patients (5%) showed cure of hypertension. This finding confirms that an association between renal artery stenosis and renovascular hypertension is a complex and multifactorial process, and that further studies are needed to identify patients who will benefit from percutaneous treatment, and to define the optimal timing for the indicated intervention.

The improvement in renal function was not as apparent as the improvement in hypertension control, a finding reported in many studies \[[@CR14]--[@CR17]\]. However, considering the population included in our study and common knowledge that renal impairment is a progressive disease which markedly reduces life expectancy and quality of life, particularly in patients who become dependent on dialysis, any stabilization of renal dysfunction and disease progression should be regarded as a beneficial outcome. According to the American Heart Association guidelines, a slowed decline in renal function is sufficient to support the claim that renal artery angioplasty is beneficial \[[@CR14]\]. In our study the best results were observed in patients with the lowest baseline e-GFR. Unfortunately the number of patients in this subgroup with long-term follow-up was relatively small, therefore, drawing any conclusion from this finding would be inappropriate. Our results are similar to some of previous reports \[[@CR16]--[@CR18]\], however, Blum et al. \[[@CR12]\] and White et al. \[[@CR9]\] found no significant change in creatinine, independent of baseline renal function. Those discrepant findings may be a result of small sample size or the inclusion of stenoses from 50% to 70% which are not hemodynamically relevant and can therefore not cause ischemic nephropathy \[[@CR19]\]. In our series of patients, however, only 16 patients (5.8%) had stenosis between 50% and 70%, bringing further controversies to this subject. Moreover, slight deterioration in renal function observed in patients with highest e-GFR at baseline is difficult to explain. It could be related to the natural progression of the disease or to a certain degree of cholesterol embolism that may put patients at risk of renal function deterioration.

The assessment of renal function and significance of RAS are also not well defined. As recently indicated by Drieghe et al. using the current criteria for RAS, a diameter stenosis \>50% by angiography falsely identifies a renal stenosis as significant in approximately 38% of cases and ultrasound does so in approximately 55% of cases \[[@CR20]\]. This indicates that the commonly accepted criteria of significant RAS overestimate the actual severity of the lesion. It is likely, therefore, that in our study as well as in the other studies that have investigated the usefulness of renal revascularization for the treatment of renovascular hypertension and renal disease progression, a sizable proportion of patients with hemodynamically non-significant stenosis might have been included. Since, in these patients, no benefit of renal artery stenting can be expected (as they had arterial hypertension or renal function impairment of other etiologies), their inclusion in these trials has most probably hazed the benefits of renal angioplasty over medical treatment.

Technical Characteristics {#Sec15}
-------------------------

The procedural performance of Tsunami stent in our study was good without occurrence of in-hospital deaths, artery perforation or rupture, or other major complications. As expected, a low crossing profile allowed direct stenting in more than 75% of lesions, including severely calcified lesions, reducing contrast dose, and radiation load and also procedure time. This finding compares favorably with other low profile platforms \[[@CR21]\].

Although large number of patients in our study did not undergo ultrasound evaluation, the 6.6% cumulative incidence of restenosis (2/91 at 6 months and 3/64 at 12  months) is comparable with findings in other contemporary trials or meta-analyses \[[@CR10], [@CR21]--[@CR23]\]

High procedural success and relatively low frequency of adverse events in our study may indicate that refinement of the devices and techniques for renal artery revascularization, along with careful patient selection could possible improve the clinical outcome after endovascular revascularization of RAS. Our aims must therefore be to improve primary and secondary prevention, achieve an earlier diagnosis, and, when indicated, appropriately treat occlusive renal disease.

Study Limitations {#Sec16}
-----------------

Our study has several limitations, the major being lack of control group which would allow the assessment of the value of the renal artery revascularization. A relatively low follow-up rate reduced the possibility of identifying patients at risk and patients expected to show benefit. This registry did not mandate follow-up by hospital visit and hence the number of ultrasound assessments is small which along with absence of an independent core-lab prevents a clear conclusion related to restenosis.

Conclusion {#Sec17}
==========

The findings of our study indicate that primary stent placement in atherosclerotic RAS is safe procedure which might be beneficial for improved control of hypertension and stabilization of renal function in patients on highest risk. Good technical success, low complication rate, low restenosis and TLR rate indicate that this stent platform could be a useful tool for further randomized controlled trials.

Appendix 1 {#Sec18}
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